Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.

Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, Xu H, Jin H, Qian Q.

Cell Death Dis. 2019 Jun 17;10(7):476. doi: 10.1038/s41419-019-1711-1.

2.

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.

Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P.

J Hematol Oncol. 2019 Feb 18;12(1):18. doi: 10.1186/s13045-019-0704-y.

3.

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.

Ye L, Lou Y, Lu L, Fan X.

Exp Ther Med. 2019 Jan;17(1):739-747. doi: 10.3892/etm.2018.7015. Epub 2018 Nov 27.

4.

Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.

Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, Zhang S, Hu J, Xu H.

J Hematol Oncol. 2018 Aug 13;11(1):102. doi: 10.1186/s13045-018-0646-9.

5.

Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma.

Xu JY, Ye ZL, Jiang DQ, He JC, Ding YM, Li LF, Lv SQ, Wang Y, Jin HJ, Qian QJ.

Tumour Biol. 2017 Apr;39(4):1010428317695949. doi: 10.1177/1010428317695949.

PMID:
28381173
6.

Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.

Zuo S, Wen Y, Panha H, Dai G, Wang L, Ren X, Fu K.

Mol Immunol. 2017 May;85:293-304. doi: 10.1016/j.molimm.2017.03.017. Epub 2017 Mar 27.

PMID:
28360017
7.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.

8.

Chimeric antigen receptor T cells: a novel therapy for solid tumors.

Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K.

J Hematol Oncol. 2017 Mar 29;10(1):78. doi: 10.1186/s13045-017-0444-9. Review.

9.

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.

Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.

10.

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.

Zhao R, Cheng L, Jiang Z, Wei X, Li B, Wu Q, Wang S, Lin S, Long Y, Zhang X, Wu Y, Du X, Pei D, Liu P, Li Y, Cui S, Yao Y, Li P.

Oncoimmunology. 2018 Nov 2;8(1):e1509173. doi: 10.1080/2162402X.2018.1509173. eCollection 2019.

11.

Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.

He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D, Zhang Q, Li L, Qin W, Jin H, Qian Q.

Cell Immunol. 2018 Jul;329:31-40. doi: 10.1016/j.cellimm.2018.04.007. Epub 2018 Apr 30.

PMID:
29859625
12.

Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.

Miyazawa M, Iwahashi M, Ojima T, Katsuda M, Nakamura M, Nakamori M, Ueda K, Naka T, Hayata K, Iida T, Yamaue H.

Cancer Lett. 2011 Jun 1;305(1):32-9. doi: 10.1016/j.canlet.2011.02.013.

PMID:
21397388
13.

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.

Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J, Xu H.

J Hematol Oncol. 2018 Mar 20;11(1):44. doi: 10.1186/s13045-018-0591-7.

14.

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.

15.

Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.

Coelho R, Marcos-Silva L, Ricardo S, Ponte F, Costa A, Lopes JM, David L.

Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186. doi: 10.1080/14737140.2018.1418326. Epub 2017 Dec 21. Review.

PMID:
29241375
16.

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

17.

The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.

Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM.

Ann N Y Acad Sci. 2009 Sep;1174:6-17. doi: 10.1111/j.1749-6632.2009.04933.x.

18.

Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C.

Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17.

19.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.

20.

T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.

Krebs S, Chow KK, Yi Z, Rodriguez-Cruz T, Hegde M, Gerken C, Ahmed N, Gottschalk S.

Cytotherapy. 2014 Aug;16(8):1121-31. doi: 10.1016/j.jcyt.2014.02.012. Epub 2014 May 16.

Supplemental Content

Support Center